Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrazoloacridine in Previously Untreated Hepatocellular Carcinoma
NCT00003714Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pyrazoloacridine in hepatocellular carcinoma (HCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate at 6 weeks, Duration of Response and 2 more. Status: withdrawn.
02
Drugs
pyrazoloacridine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00003714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003714.